Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.

Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.

J Am Soc Nephrol. 2019 Jun 14. pii: ASN.2019050450. doi: 10.1681/ASN.2019050450. [Epub ahead of print]

PMID:
31201218
2.

Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.

Denison H, Nilsson C, Löfgren L, Himmelmann A, Mårtensson G, Knutsson M, Al-Shurbaji A, Tornqvist H, Eriksson JW.

Diabetes Obes Metab. 2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct 31.

PMID:
24118885
3.

The effect of intravenously administered mexiletine on tinnitus - a pilot study.

Berninger E, Nordmark J, Alván G, Karlsson KK, Idrizbegovic E, Meurling L, Al-Shurbaji A.

Int J Audiol. 2006 Dec;45(12):689-96.

PMID:
17132557
4.

Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein.

Yasar U, Annas A, Svensson JO, Lazorova L, Artursson P, Al-Shurbaji A.

Xenobiotica. 2005 Aug;35(8):785-96.

PMID:
16278191
5.

Spontaneous cerebrospinal fluid rhinorrhea through clival defect.

Al-Shurbaji AA, Abu-Salma ZA.

Neurosciences (Riyadh). 2005 Jul;10(3):232-4.

PMID:
22473266
6.

The advantage of the Gigli saw in performing mid-frontobasal craniotomy over the power driven tools.

Al-Shurbaji AA, Mubaideen AF.

Neurosciences (Riyadh). 2005 Jan;10(1):110-1. No abstract available.

PMID:
22473203
7.
8.

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.

Lindh JD, Annas A, Meurling L, Dahl ML, AL-Shurbaji A.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):401-6. Epub 2003 Jul 25.

PMID:
12898080
9.

The pharmacokinetics of ketobemidone in critically ill patients.

Al-Shurbaji A, Tokics L.

Br J Clin Pharmacol. 2002 Dec;54(6):583-6.

10.

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.

Al-Shurbaji A, Säwe J.

Eur J Clin Pharmacol. 2002 Feb;57(12):877-81.

PMID:
11936707
11.

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A.

Br J Clin Pharmacol. 2002 Feb;53(2):111-22. Review.

12.

Quantitative pharmacogenetics of nortriptyline: a novel approach.

Kvist EE, Al-Shurbaji A, Dahl ML, Nordin C, Alván G, Ståhle L.

Clin Pharmacokinet. 2001;40(11):869-77.

PMID:
11735606
13.
14.

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

Hassan M, Svensson JO, Nilsson C, Hentschke P, Al-Shurbaji A, Aschan J, Ljungman P, Ringdén O.

Ther Drug Monit. 2000 Aug;22(4):383-5.

PMID:
10942175
15.

Hepatic cholesterol metabolism in experimental nephrotic syndrome.

al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L.

Lipids. 1998 Feb;33(2):165-9.

PMID:
9507238
16.

On the interrelationship between hepatic carnitine, fatty acid oxidation, and triglyceride biosynthesis in nephrosis.

al-Shurbaji A, Berglund L, Berge RK, Cederblad G, Humble E.

Lipids. 1997 Aug;32(8):847-52.

PMID:
9270976
17.

Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids.

Asiedu DK, al-Shurbaji A, Rustan AC, Björkhem I, Berglund L, Berge RK.

Eur J Biochem. 1995 Feb 1;227(3):715-22.

18.

Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors.

Humble E, al-Shurbaji A, Lund E, Berglund L.

Biochim Biophys Acta. 1994 Aug 25;1214(1):32-8.

PMID:
8068726
19.

Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis.

al-Shurbaji A, Skorve J, Berge RK, Rudling M, Björkhem I, Berglund L.

Arterioscler Thromb. 1993 Nov;13(11):1580-6.

PMID:
8218098
20.

On the mechanism of the hypolipidemic effect of sulfur-substituted hexadecanedioic acid (3-thiadicarboxylic acid) in normolipidemic rats.

Skorve J, al-Shurbaji A, Asiedu D, Björkhem I, Berglund L, Berge RK.

J Lipid Res. 1993 Jul;34(7):1177-85.

21.

Effect of n-3 fatty acids on the key enzymes involved in cholesterol and triglyceride turnover in rat liver.

al-Shurbaji A, Larsson-Backström C, Berglund L, Eggertsen G, Björkhem I.

Lipids. 1991 May;26(5):385-9.

PMID:
1895886
22.

Regulation of fatty acid oxidation and triglyceride and phospholipid metabolism by hypolipidemic sulfur-substituted fatty acid analogues.

Skorve J, Asiedu D, Rustan AC, Drevon CA, al-Shurbaji A, Berge RK.

J Lipid Res. 1990 Sep;31(9):1627-35.

23.

The effect of Acipimox on triacylglycerol metabolism in rat.

al-Shurbaji A, Berglund L, Björkhem I.

Scand J Clin Lab Invest. 1990 Apr;50(2):203-8.

PMID:
2339282
24.

Apparent lack of effect of obesity on the soluble phosphatidic acid phosphatase activity in human adipose tissue.

Björkhem I, al-Shurbaji A, Backman L, Arner P.

Lipids. 1989 Dec;24(12):1048-52.

PMID:
2559280
25.

Supplemental Content

Loading ...
Support Center